Table 2.

Association of candidate variants with CMV reactivation and CMV disease after allogeneic HCT

Discovery resultsReplication results
ChrGeneSNPAlleles*GenomeEnd pointModelMAF†P valueHRLBUBBf-CP valueHRLBUBPower‡
7 ABCB1 rs1045642 A/G Donor Any R D 0.47 .002 0.74 0.62 0.89 0.05 .03 0.79 0.64 0.97 80 
2 IL1B rs16944 G/A Donor HLR A 0.34 .0006 0.68 0.55 0.85 0.05 .27 0.86 0.66 1.12  
2 IL1B rs16944 G/A Donor HLR D 0.34 .004 0.67 0.51 0.88 0.05 .29 0.83 0.59 1.17  
2 CD28 rs3116496 T/C Recipient Any R A 0.19 .003 1.26 1.09 1.46 0.025 .28 1.11 0.92 1.33 60 
2 CD28 rs3116496 T/C Recipient Any R D 0.19 .003 1.30 1.09 1.54 0.025 .23 1.14 0.92 1.40 57 
11 IL10RA rs3135932 A/G Recipient Any R R 0.18 .005 0.42 0.21 0.85 0.025 .41 1.28 0.73 2.23 79 
3 PTX3§ rs2305619 G/A Recipient HLR A 0.49 .002 1.37 1.12 1.67 0.05 .98 1.00 0.79 1.26  
2 CTLA4 rs231775 A/G Recipient Disease A 0.37 .0001 1.48 1.21 1.81 0.01 .02 0.71 0.53 0.95 52 
2 CTLA4 rs231775 A/G Recipient Disease D 0.37 .0009 1.66 1.22 2.26 0.01 .02 0.65 0.44 0.94 53 
2 CTLA4 rs231775 A/G Recipient Disease R 0.37 .005 1.70 1.20 2.40 0.01 .19 0.66 0.34 1.26 16 
2 CTLA4 rs3087243 G/A Recipient Disease A 0.46 .004 0.75 0.61 0.92 0.01 .25 1.17 0.89 1.53 32 
2 CTLA4 rs3087243 G/A Recipient Disease D 0.46 .004 0.65 0.49 0.87 0.01 .38 1.21 0.79 1.86 26 
19 LILRB1 rs1061680 T/C Recipient Disease R 0.27 .004 0.38 0.18 0.82 0.01 .42 1.34 0.68 2.66 56 
22 PPARA rs4253728 G/A Recipient Disease A 0.28 .004 0.67 0.50 0.89 0.01 .82 1.05 0.71 1.53 31 
22 PPARA rs4253728 G/A Recipient Disease D 0.28 .001 0.57 0.40 0.80 0.01 .72 1.09 0.68 1.74 42 
Discovery resultsReplication results
ChrGeneSNPAlleles*GenomeEnd pointModelMAF†P valueHRLBUBBf-CP valueHRLBUBPower‡
7 ABCB1 rs1045642 A/G Donor Any R D 0.47 .002 0.74 0.62 0.89 0.05 .03 0.79 0.64 0.97 80 
2 IL1B rs16944 G/A Donor HLR A 0.34 .0006 0.68 0.55 0.85 0.05 .27 0.86 0.66 1.12  
2 IL1B rs16944 G/A Donor HLR D 0.34 .004 0.67 0.51 0.88 0.05 .29 0.83 0.59 1.17  
2 CD28 rs3116496 T/C Recipient Any R A 0.19 .003 1.26 1.09 1.46 0.025 .28 1.11 0.92 1.33 60 
2 CD28 rs3116496 T/C Recipient Any R D 0.19 .003 1.30 1.09 1.54 0.025 .23 1.14 0.92 1.40 57 
11 IL10RA rs3135932 A/G Recipient Any R R 0.18 .005 0.42 0.21 0.85 0.025 .41 1.28 0.73 2.23 79 
3 PTX3§ rs2305619 G/A Recipient HLR A 0.49 .002 1.37 1.12 1.67 0.05 .98 1.00 0.79 1.26  
2 CTLA4 rs231775 A/G Recipient Disease A 0.37 .0001 1.48 1.21 1.81 0.01 .02 0.71 0.53 0.95 52 
2 CTLA4 rs231775 A/G Recipient Disease D 0.37 .0009 1.66 1.22 2.26 0.01 .02 0.65 0.44 0.94 53 
2 CTLA4 rs231775 A/G Recipient Disease R 0.37 .005 1.70 1.20 2.40 0.01 .19 0.66 0.34 1.26 16 
2 CTLA4 rs3087243 G/A Recipient Disease A 0.46 .004 0.75 0.61 0.92 0.01 .25 1.17 0.89 1.53 32 
2 CTLA4 rs3087243 G/A Recipient Disease D 0.46 .004 0.65 0.49 0.87 0.01 .38 1.21 0.79 1.86 26 
19 LILRB1 rs1061680 T/C Recipient Disease R 0.27 .004 0.38 0.18 0.82 0.01 .42 1.34 0.68 2.66 56 
22 PPARA rs4253728 G/A Recipient Disease A 0.28 .004 0.67 0.50 0.89 0.01 .82 1.05 0.71 1.53 31 
22 PPARA rs4253728 G/A Recipient Disease D 0.28 .001 0.57 0.40 0.80 0.01 .72 1.09 0.68 1.74 42 

Rows demarcated by lines indicate genome-phenotype combinations.

A, allelic; Any R, any reactivation; Bf-C, Bonferroni correction; Chr, chromosome; D, dominant; HLR, high-level reactivation; LB, lower boundary of the 95% CI; R, recessive; UB, upper boundary of the 95% CI.

*

Plus-strand major/minor alleles; allele designations may differ from those used in previous studies.

†

MAF in the combined donor and recipient samples used for the evaluation.

‡

Power is based on the discovery HR point estimate and estimated standard error of the replication log HR, with a Bonferroni-corrected significance level reflecting the number of discovery findings.

§

Also VEPH1.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal